Actinium Treats First Patient In AML Study On Actimab-A Combo
Zacks Investment Research | Mar 05, 2020 10:56PM ET
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) announced that the first patient has begun treatment in the third and final cohort of an investigator-led phase I study, evaluating a combination of Actimab-A with a chemotherapy regimen, CLAG-M.
This phase I study is being conducted in patients with relapsed or refractory acute myeloid leukemia (AML). Actimab-A is an antibody radiation conjugate (ARC). Actinium's lead application for ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a bone marrow transplant, gene therapy or adoptive cell therapy.
The study is being conducted at the Medical College of Wisconsin. The objectives of the study are to evaluate the safety, determine the maximum tolerated dose and response rates, progression-free survival, and overall survival. The overall response has been 86% so far, better than other approaches.
Patients in the third cohort will receive a chemotherapy cycle of CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone), followed by 0.75 uCi/kg dose of Actimab-A on Day 6, 7 or 8. The cohort should be completed bymid-2020.
Shares of the company have slumped 50% in the past year compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.